A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Trial Profile

A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms T3MPO-2
  • Sponsors Ardelyx
  • Most Recent Events

    • 07 Nov 2017 According to an Ardelyx media release, the company expects to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the second half of 2018 seeking marketing authorization for tenapanor in IBS-C.
    • 11 Oct 2017 Results presented in an Ardelyx media release.
    • 11 Oct 2017 Primary endpoint (Percentage of Subjects with Overall Response for 6 out of 12 Weeks) has been met according to an Ardelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top